However, as observed in the SURPASS-5, daily insulin dose remained similar in participants randomized to TZP 5 and 10 mg and was mildly reduced in those assuming TZP 15 mg
Your GP can advise on local pathways and eligibility
This strategy not only reassures patients but also aligns with broader advocacy efforts, such as Novo Nordisks and Eli Lillys petitions against unsafe compounding practices
Avoid driving or using machines if you get any signs of low blood sugar, e.g., headache, drowsiness, weakness, dizziness, feeling hungry, confusion, irritability, feast heartbeat and sweating
Most patients do not see the full weight loss benefit of a given dose until they have been on it for 8 to 12 weeks
Patient-reported outcomes Carefully selected patient-reported outcome (PRO) instruments (standardised questionnaires designed to understand the patient experience) were administered at baseline and at 40 or 52 weeks across the SURPASS clinical trial programme (Boye et al, 2023)